{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:54:30Z","timestamp":1794466470209,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Comorbid mental disorders in subjects at clinical high risk for psychosis (CHR-P) may impact preventive care. We conducted a PRISMA\/MOOSE-compliant systematic meta-analysis, searching PubMed\/PsycInfo up to June 21st, 2021 for observational studies\/randomized controlled trials reporting on comorbid DSM\/ICD-mental disorders in CHR-P subjects (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/osf.io\/f2t6w\/?view_only=fe08c02e1e9e45b09d101ad5c3c84fee%0c\">protocol<\/jats:ext-link>\n                    ). The primary and secondary outcomes were baseline and follow-up prevalence of comorbid mental disorders. We also explored the association of comorbid mental disorders compared with CHR-P versus psychotic\/non-psychotic control groups, their impact on baseline functioning and transition to psychosis. We conducted random-effects meta-analyses, meta-regression, and assessed heterogeneity\/publication bias\/quality (Newcastle Ottawa Scale, NOS). We included 312 studies (largest meta-analyzed sample\u2009=\u20097834, any anxiety\u00a0disorder, mean age\u2009=\u200919.98 (3.40), females\u2009=\u200943.88%, overall NOS\u2009&gt;\u20096 in 77.6% of studies). The prevalence was 0.78 (95% CI\u2009=\u20090.73\u20130.82,\n                    <jats:italic>k<\/jats:italic>\n                    \u2009=\u200929) for any comorbid non-psychotic\u00a0mental disorder, 0.60 (95% CI\u2009=\u20090.36\u20130.84,\n                    <jats:italic>k<\/jats:italic>\n                    \u2009=\u20093) for anxiety\/mood disorders, 0.44 (95% CI\u2009=\u20090.39\u20130.49,\n                    <jats:italic>k<\/jats:italic>\n                    \u2009=\u200948) for any mood disorders, 0.38 (95% CI\u2009=\u20090.33\u20130.42,\n                    <jats:italic>k<\/jats:italic>\n                    \u2009=\u200950) for any depressive disorder\/episode, 0.34 (95% CI\u2009=\u20090.30\u20130.38,\n                    <jats:italic>k<\/jats:italic>\n                    \u2009=\u200969) for any anxiety disorder, 0.30 (95% CI 0.25\u20130.35,\n                    <jats:italic>k<\/jats:italic>\n                    \u2009=\u200935) for major depressive disorders, 0.29 (95% CI, 0.08\u20130.51,\n                    <jats:italic>k<\/jats:italic>\n                    \u2009=\u20093) for any trauma-related disorder, 0.23 (95% CI\u2009=\u20090.17\u20130.28,\n                    <jats:italic>k<\/jats:italic>\n                    \u2009=\u200924) for any personality disorder, and &lt;0.23 in other mental disorders (I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009&gt;\u200950% in 71.01% estimates). The prevalence of any comorbid mental disorder decreased over time (0.51, 95% CI\u2009=\u20090.25\u20130.77 over 96 months), except any substance use which increased (0.19, 95% CI\u2009=\u20090.00\u20130.39,\n                    <jats:italic>k<\/jats:italic>\n                    \u2009=\u20092, &gt;96 months). Compared with controls, the CHR-P status was associated with a higher prevalence of anxiety, schizotypal personality, panic, and alcohol use disorders (OR from 2.90 to 1.54 versus without psychosis), a higher prevalence of anxiety\/mood disorders (OR\u2009=\u20099.30 to 2.02) and lower prevalence of any substance use disorder (OR\u2009=\u20090.41, versus psychosis). Higher baseline prevalence of alcohol use disorder\/schizotypal personality disorder was negatively associated with baseline functioning (beta from \u22120.40 to \u22120.15), while dysthymic disorder\/generalized anxiety disorder with higher functioning (beta 0.59 to 1.49). Higher baseline prevalence of any mood disorder\/generalized anxiety disorder\/agoraphobia (beta from \u22122.39 to \u22120.27) was negatively associated with transition to psychosis. In conclusion, over three-quarters of CHR-P subjects have comorbid mental disorders, which modulate baseline functionig and transition to psychosis. Transdiagnostic mental health assessment should be warranted in subjects at CHR-P.\n                  <\/jats:p>","DOI":"10.1038\/s41380-023-02029-8","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T01:02:25Z","timestamp":1686272545000},"page":"2291-2300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-0561","authenticated-orcid":false,"given":"Livia","family":"Soardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simi","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Azis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cabras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Censori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Fausti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Besana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6992-0767","authenticated-orcid":false,"given":"Gonzalo","family":"Salazar de Pablo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-6788","authenticated-orcid":false,"given":"Paolo","family":"Fusar-Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"2029_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/wps.20869","volume":"20","author":"P Fusar-Poli","year":"2021","unstructured":"Fusar-Poli P, Correll C, Arango C, Berk M, Patel V, Ioannidis J. Preventive psychiatry: a blueprint for improving the mental health of young people. World Psychiatry. 2021;20:200\u201321.","journal-title":"World Psychiatry"},{"key":"2029_CR2","doi-asserted-by":"publisher","unstructured":"Catalan A, Salazar de Pablo G, Vaquerizo Serrano J, Mosillo P, Baldwin H, Fern\u00e1ndez-Rivas A, et al. Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention. J Child Psychol Psychiatry. 2020. https:\/\/doi.org\/10.1111\/jcpp.13322.","DOI":"10.1111\/jcpp.13322"},{"key":"2029_CR3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamapsychiatry.2019.4779","volume":"77","author":"P Fusar-Poli","year":"2020","unstructured":"Fusar-Poli P, Salazar De Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, et al. Prevention of psychosis: advances in detection, prognosis, and intervention. JAMA Psychiatry. 2020;77:755\u201365.","journal-title":"JAMA Psychiatry"},{"key":"2029_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/jamapsychiatry.2019.3561","volume":"77","author":"G Salazar de Pablo","year":"2020","unstructured":"Salazar de Pablo G, Catalan A, Fusar-Poli P. Clinical validity of DSM-5 attenuated psychosis syndrome: advances in diagnosis, prognosis, and treatment. JAMA Psychiatry. 2020;77:311\u201320.","journal-title":"JAMA Psychiatry"},{"key":"2029_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamapsychiatry.2021.0830","volume":"78","author":"G Salazar De Pablo","year":"2021","unstructured":"Salazar De Pablo G, Radua J, Pereira J, Bonoldi I, Arienti V, Besana F, et al. Probability of transition to psychosis in individuals at clinical high risk: an updated meta-analysis. JAMA Psychiatry. 2021;78:970\u20138.","journal-title":"JAMA Psychiatry"},{"key":"2029_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1001\/jamapsychiatry.2021.1290","volume":"78","author":"A Catalan","year":"2021","unstructured":"Catalan A, Salazar de Pablo G, Aymerich C, Damiani S, Sordi V, Radua J, et al. Neurocognitive functioning in individuals at clinical high risk for psychosis: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78:859\u201367.","journal-title":"JAMA Psychiatry"},{"key":"2029_CR7","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/brainsci11111544","volume":"11","author":"G Salazar de Pablo","year":"2021","unstructured":"Salazar de Pablo G, Woods SW, Drymonitou G, de Diego H, Fusar-Poli P. Prevalence of individuals at clinical high-risk of psychosis in the general population and clinical samples: systematic review and meta-analysis. Brain Sci. 2021;11:1544.","journal-title":"Brain Sci"},{"key":"2029_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/j.1440-1614.2005.01714.x","volume":"39","author":"AR Yung","year":"2005","unstructured":"Yung AR, Pan Yuen H, Mcgorry PD, Phillips LJ, Kelly D, Dell\u2019Olio M, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Zeal J Psychiatry. 2005;39:964\u201371.","journal-title":"Aust N Zeal J Psychiatry"},{"key":"2029_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/oxfordjournals.schbul.a007040","volume":"29","author":"TJ Miller","year":"2003","unstructured":"Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703\u201315.","journal-title":"Schizophr Bull"},{"key":"2029_CR10","doi-asserted-by":"publisher","unstructured":"Oliver D, Arribas M, Radua J, Salazar de Pablo G, De Micheli A, Spada G, et al. Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis. Mol Psychiatry. 2022. 2022. https:\/\/doi.org\/10.1038\/s41380-022-01611-w.","DOI":"10.1038\/s41380-022-01611-w"},{"key":"2029_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/schbul\/sbs136","volume":"40","author":"P Fusar-Poli","year":"2014","unstructured":"Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull. 2014;40:120\u201331.","journal-title":"Schizophr Bull"},{"key":"2029_CR12","first-page":"24","volume":"23","author":"M Solmi","year":"2020","unstructured":"Solmi M, Campeol M, Gentili F, Favaro A, Cremonese C. Clinical presentation and need for treatment of a cohort of subjects accessing to a mental illness prevention service. Res Psychother Psychopathol Process Outcome. 2020;23:24\u201332.","journal-title":"Res Psychother Psychopathol Process Outcome"},{"key":"2029_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jad.2016.05.053","volume":"203","author":"G Rutigliano","year":"2016","unstructured":"Rutigliano G, Valmaggia L, Landi P, Frascarelli M, Cappucciati M, Sear V, et al. Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. J Affect Disord. 2016;203:101\u201310.","journal-title":"J Affect Disord"},{"key":"2029_CR14","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1192\/j.eurpsy.2021.2222","volume":"64","author":"G Salazar de Pablo","year":"2021","unstructured":"Salazar de Pablo G, Davies C, de Diego H, Solmi M, Shin JI, Carvalho AF, et al. Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis. Eur Psychiatry. 2021;64:e51.","journal-title":"Eur Psychiatry"},{"key":"2029_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/schbul\/sbab088","volume":"48","author":"F Schirmbeck","year":"2022","unstructured":"Schirmbeck F, van der Burg NC, Blankers M, Vermeulen JM, McGuire P, Valmaggia LR, et al. Impact of comorbid affective disorders on longitudinal clinical outcomes in individuals at ultra-high risk for psychosis. Schizophr Bull. 2022;48:100\u201310.","journal-title":"Schizophr Bull"},{"key":"2029_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.schres.2012.03.008","volume":"138","author":"RKR Salokangas","year":"2012","unstructured":"Salokangas RKR, Ruhrmann S, von Reventlow HG, Heinimaa M, Svirskis T, From T, et al. Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: Prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophr Res. 2012;138:192\u20137.","journal-title":"Schizophr Res"},{"key":"2029_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.schres.2015.03.007","volume":"164","author":"J Lim","year":"2015","unstructured":"Lim J, Rekhi G, Rapisarda A, Lam M, Kraus M, Keefe RSE, et al. Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis \u2014 Findings from the Longitudinal Youth at Risk Study (LYRIKS). Schizophr Res. 2015;164:8\u201314.","journal-title":"Schizophr Res"},{"key":"2029_CR18","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.eclinm.2021.100909","volume":"36","author":"G de Pablo","year":"2021","unstructured":"de Pablo G, Besana F, Arienti V, Catalan A, Vaquerizo-Serrano J, Cabras A, et al. Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. EClinicalMedicine. 2021;36:100909.","journal-title":"EClinicalMedicine"},{"key":"2029_CR19","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1017\/S2045796021000639","volume":"31","author":"G Salazar de Pablo","year":"2022","unstructured":"Salazar de Pablo G, Soardo L, Cabras A, Pereira J, Kaur S, Besana F, et al. Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis. Epidemiol Psychiatr Sci. 2022;31:e9\u2013e9.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2029_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2029_CR21","doi-asserted-by":"crossref","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D. MOOSE guidelines for meta-analyses and systematic reviews of observational studies. JAMA. 2000;283:2008\u201312.","DOI":"10.1001\/jama.283.15.2008"},{"key":"2029_CR22","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2029_CR23","unstructured":"WHO. International Classification of Diseases - 11 (ICD-11). Version: 2020. WHO, 2019."},{"key":"2029_CR24","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. 2012, https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"2029_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"2029_CR26","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"CJL Murray","year":"2020","unstructured":"Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223\u201349.","journal-title":"Lancet"},{"key":"2029_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01805-4","volume":"12","author":"A Estrad\u00e9","year":"2022","unstructured":"Estrad\u00e9 A, Salazar de Pablo G, Zanotti A, Wood S, Fisher HL, Fusar-Poli P. Public health primary prevention implemented by clinical high-risk services for psychosis. Transl Psychiatry. 2022;12:43.","journal-title":"Transl Psychiatry"},{"key":"2029_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/schbul\/sbs155","volume":"39","author":"AL Mishara","year":"2013","unstructured":"Mishara AL, Fusar-Poli P. The phenomenology and neurobiology of delusion formation during psychosis onset: Jaspers, Truman symptoms, and aberrant salience. Schizophr Bull. 2013;39:278\u201386.","journal-title":"Schizophr Bull"},{"key":"2029_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/wps.20755","volume":"19","author":"S Guloksuz","year":"2020","unstructured":"Guloksuz S, Pries L-K, Ten Have M, de Graaf R, van Dorsselaer S, Klingenberg B, et al. Association of preceding psychosis risk states and non-psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESIS-2 cohort. World Psychiatry. 2020;19:199\u2013205.","journal-title":"World Psychiatry"},{"key":"2029_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/wps.20631","volume":"18","author":"P Fusar-Poli","year":"2019","unstructured":"Fusar-Poli P, Solmi M, Brondino N, Davies C, Chae C, Politi P, et al. Transdiagnostic psychiatry: a systematic review. World Psychiatry. 2019;18:192\u2013207.","journal-title":"World Psychiatry"},{"key":"2029_CR31","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3389\/fpsyt.2019.00774","volume":"10","author":"P Fusar-Poli","year":"2019","unstructured":"Fusar-Poli P, Sullivan SA, Shah JL, Uhlhaas PJ. Improving the detection of individuals at clinical risk for psychosis in the community, primary and secondary care: An integrated evidence-based approach. Front Psychiatry. 2019;10:774.","journal-title":"Front Psychiatry"},{"key":"2029_CR32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1001\/jamapsychiatry.2017.1009","volume":"74","author":"P Fusar-Poli","year":"2017","unstructured":"Fusar-Poli P. Extending the benefits of indicated prevention to improve outcomes of first-episode psychosis. JAMA Psychiatry. 2017;74:667\u20138.","journal-title":"JAMA Psychiatry"},{"key":"2029_CR33","unstructured":"NICE. 1 Recommendations, Psychosis and schizophrenia in adults: prevention and management, Guidance, NICE. 2014. https:\/\/www.nice.org.uk\/guidance\/cg178."},{"key":"2029_CR34","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.psychres.2015.05.018","volume":"228","author":"I Falkenberg","year":"2015","unstructured":"Falkenberg I, Valmaggia L, Byrnes M, Frascarelli M, Jones C, Rocchetti M, et al. Why are help-seeking subjects at ultra-high risk for psychosis help-seeking? Psychiatry Res. 2015;228:808\u201315.","journal-title":"Psychiatry Res"},{"key":"2029_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eurpsy.2016.11.010","volume":"42","author":"P Fusar-Poli","year":"2017","unstructured":"Fusar-Poli P, Rutigliano G, Stahl D, Davies C, De Micheli A, Ramella-Cravaro V, et al. Long-term validity of the At Risk Mental State (ARMS) for predicting psychotic and non-psychotic mental disorders. Eur Psychiatry. 2017;42:49\u201354.","journal-title":"Eur Psychiatry"},{"key":"2029_CR36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.psychres.2018.03.074","volume":"264","author":"P Fusar-Poli","year":"2018","unstructured":"Fusar-Poli P, De Micheli A, Rocchetti M, Cappucciati M, Ramella-Cravaro V, Rutigliano G, et al. Semistructured Interview for Bipolar At Risk States (SIBARS). Psychiatry Res. 2018;264:302\u20139.","journal-title":"Psychiatry Res"},{"key":"2029_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/bdi.12209","volume":"16","author":"CU Correll","year":"2014","unstructured":"Correll CU, Olvet DM, Auther AM, Hauser M, Kishimoto T, Carri\u00f3n RE, et al. The Bipolar Prodrome Symptom Interview and Scale-Prospective (BPSS-P): description and validation in a psychiatric sample and healthy controls. Bipolar Disord. 2014;16:505\u201322.","journal-title":"Bipolar Disord"},{"key":"2029_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1089\/cap.2021.0071","volume":"32","author":"\u015eY Sapmaz","year":"2022","unstructured":"Sapmaz \u015eY, Ermi\u015f \u00c7, \u00c7aklr B, \u00d6ztekin S, Guinart D, Al\u015fen G\u00fcney S, et al. Reliability and validity of the bipolar prodrome symptom interview and scale-full prospective in its Turkish translation. J Child Adolesc Psychopharmacol. 2022;32:178\u201386.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2029_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jad.2019.02.040","volume":"249","author":"A Van Meter","year":"2019","unstructured":"Van Meter A, Guinart D, Bashir A, Sareen A, Cornblatt BA, Auther A, et al. Bipolar prodrome symptom scale - abbreviated screen for patients: description and validation. J Affect Disord. 2019;249:357\u201365.","journal-title":"J Affect Disord"},{"key":"2029_CR40","doi-asserted-by":"publisher","unstructured":"Dragioti E, Radua J, Solmi M, Arango C, Oliver D, Cortese S, et al. Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. Mol Psychiatry. 2022. 2022. https:\/\/doi.org\/10.1038\/s41380-022-01586-8.","DOI":"10.1038\/s41380-022-01586-8"},{"key":"2029_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/wps.20894","volume":"20","author":"C Arango","year":"2021","unstructured":"Arango C, Dragioti E, Solmi M, Cortese S, Domschke K, Murray RM, et al. Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. World Psychiatry. 2021;20:417\u201336.","journal-title":"World Psychiatry"},{"key":"2029_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry. 2018;175:225\u201331.","journal-title":"Am J Psychiatry"},{"key":"2029_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","volume":"27","author":"M Solmi","year":"2021","unstructured":"Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2021;27:281\u201395.","journal-title":"Mol Psychiatry"},{"key":"2029_CR44","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/schbul\/sbv162","volume":"42","author":"P Fusar-Poli","year":"2016","unstructured":"Fusar-Poli P, Schultze-Lutter F, Cappucciati M, Rutigliano G, Bonoldi I, Stahl D, et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. 2016;42:732\u201343.","journal-title":"Schizophr Bull"},{"key":"2029_CR45","first-page":"434","volume":"23","author":"M Solmi","year":"2020","unstructured":"Solmi M, Campeol M, Gentili F, Favaro A, Cremonese C. Clinical presentation and need for treatment of a cohort of subjects accessing to a mental illness prevention service. Res Psychother. 2020;23:434.","journal-title":"Res Psychother"},{"key":"2029_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/wps.20446","volume":"16","author":"P Fusar-Poli","year":"2017","unstructured":"Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. World Psychiatry. 2017;16:251\u201365.","journal-title":"World Psychiatry"},{"key":"2029_CR47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234\u201358.","journal-title":"Drug Alcohol Depend"},{"key":"2029_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.schres.2010.03.015","volume":"120","author":"S Ruhrmann","year":"2010","unstructured":"Ruhrmann S, Schultze-Lutter F, Klosterk\u00f6tter J. Probably at-risk, but certainly ill \u2014 Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res. 2010;120:23\u201337.","journal-title":"Schizophr Res"},{"key":"2029_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/wps.20423","volume":"16","author":"J van Os","year":"2017","unstructured":"van Os J, Guloksuz S. A critique of the \u201cultra-high risk\u201d and \u201ctransition\u201d paradigm. World Psychiatry. 2017;16:200\u20136.","journal-title":"World Psychiatry"},{"key":"2029_CR50","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamapsychiatry.2016.2707","volume":"73","author":"P Fusar-Poli","year":"2016","unstructured":"Fusar-Poli P, Rutigliano G, Stahl D, Schmidt A, Ramella-Cravaro V, Hitesh S, et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry. 2016;73:1260\u20137.","journal-title":"JAMA Psychiatry"},{"key":"2029_CR51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jamapsychiatry.2015.2324","volume":"73","author":"P Fusar-Poli","year":"2016","unstructured":"Fusar-Poli P, Cappucciati M, Borgwardt S, Woods SW, Addington J, Nelson B, et al. Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. JAMA Psychiatry. 2016;73:113\u201320.","journal-title":"JAMA Psychiatry"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02029-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02029-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02029-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T04:07:56Z","timestamp":1698379676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02029-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1038\/s41380-023-02029-8","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MS received honoraria\/has been a consultant for Angelini, Lundbeck, Otsuka. PFP has received research funds or personal fees from Lundbeck, Angelini, Menarini, Sunovion, Boehringer Ingelheim, Mindstrong, Proxymm Science, outside the current study. GSdP reports honoraria from Janssen-Cilag and Angelini. GSdP is supported by the Alicia Koplowitz Foundation. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}